provided our afternoon, execution, and commercial closed regulatory commentary of strategically APT. in and significant acquisition are I'm good parallel demonstrated APT successfully and transformational. the efforts last are operator, quarter. We that innovation you, pleased Thank call, our On innovation with strategy and performance integrated a this solid range I everyone. on our advancing broad and
today's I'll we'll Q&A. focus then open updates. relatively share keep the will to call remarks to brief with Kim and the on just our results, financial key
Genesis third was to partial in delivered driven quarter. growth customers late the revenue in Our quarter that systems the were of predominantly X by revenue recognition
All establishing European X which of their existing X and entirely labs are an which new upgrading of one were to program. Genesis to robotic is hospitals, delivered robotic
our announce their first we been treat As will they in Genesis coordination each as patients. has custom, with hospital launches
Genesis pipeline we X for orders in robust, quarter. Genesis remains systems Our received additional the and third customers of
The combination left of with of revenue million and of orders backlog end capital the these at the quarter. system $XX.X third a us incremental
Genesis CE robotic a to of adds ultimately incrementally opportunity. for to see start receive recent GenesisX an coming GenesisX our customers our We to to continue and of pipeline has us build active interested mark This to and will customers Genesis The to quarters. continue pipeline allowed dwarf expect in orders pipeline this GenesisX that pipeline. in
to to it launch catheter, our CE similar first system near received at in of as around we which Mark order. GenesisX GenesisX, not is have the we expect expect milestone, While MAGIC that approval time term. receive a the we yet the key for
trajectory. see very on and hospitals GenesisX overall the our growth start will are impact We on have to to excited physicians, patients,
where China States Europe, increasingly to advanced and driven into have we regulatory United forward Europe, Our contributing ecosystem coming behind capital With predominantly we fruition. our and product most slightly have geographies to revenue. the results orders capital by been those look the in approvals
Our have remained specialty. fully electrophysiology by orders driven the robotic also historically system
introduced we year, forward we to vascular partial catheters driven and revenue of the revenue orders from In acquisition the in a the to the receive benefited coming quarter first broader as look third specialties. guidewires, of quarter starting by Recurring APT. from of contribution the catheter array
in $X.X in third quarter. fourth approximately was the be contribution million the larger This and quarter will
the in catheters reception by are robotic our APT's excited to from of customers electrophysiologists. positive We the community
quarters. growth We expect and in the subsequent fourth meaningful sequential revenue catheters these from
acquisition commercial our the I early commercial that I'm months call, synergy with following described validate these as the synergy catheters. well to strategy last and strategy. clinical as the on and the pleased the differentiated continue
segways navigated the approvals While guidance our of opportunity of in our strategy. into catheters launches supporting innovation and revenue robotically addition commercial regulatory to with and That mapping is updates remains revenue, recurring catheters largest well of APT us a ahead ablation vascular growth wires. and return and recurring on
European driving aggressively is stages innovation late our navigated cardiac robotically catheter, progress broad-based are We to The ablation strategy. across of MAGIC a close comprehensive proprietary receiving Mark the catheter approval. CE
received been brief of microbiology review, questions those microbiology. completed. questions, the We a During round review on second clarification following questions, are and final responded confirmation earnings to last area we the quarter, has outstanding received that third call, awaiting our our of
for Mark afterwards. CE receive should MAGIC shortly We
PMA positive its in are we feedback study customers. of looking submission, collaborative our our We continuing robotic the FDA continue In approval and expect from given and to of received experience U.S., European dialogue. the MAGIC the the and to is much significant we forward community very adoption thoughtful and MAGIC commercial ongoing have review clinical of
aligned expected data support indication. for should that an that We and on the MAGIC indication have
expectation U.S. of of We ongoing in plan ongoing subsequent The with and MAGIC are appreciate for depend appreciation achieving initial patients on a MAGIC available nature it. our the the who a data becomes supports these generated the European studies physicians being of discussions for the collaborative dialogue believe an they study shared importance reflective ensuring post-approval and leveraging of clear regulatory in the approval,
development robotic Beyond completed with of advanced guidance of acquisition. high-density being made catheters couple be time Both catheter. the the of the and vascular we mapping MAGIC, and progress will what last years catheter were with first-ever significant around the these over APT
a third catheters up of During early quarter us regulatory to for all formal and hundreds the couple quarter, for within complete of testing next setting submissions in we needed regulatory manufactured months, XXXX. testing expect the
catheters significant clinically, Both value provide and strategically. commercially
at may Some catheters X color of in very customers recent the the weeks anecdotal helpful. in the opportunity X annual Navigation Cardiac for on dozens Society be these Robotic our to conference Portugal. ago have meet with interest I
Immediately after focus ecosystem conference At the there the in robotics. product the French and was warranting emerging particular the in importance how on mapping physicians our of of our a at the that, one barrier catheter both have prestigious interest comprehensive field. reassessing on EP this catheter primary of globally at can and hospital and visited to centers physician robotics France. robotic significant addresses and mapping the highlights well-respected The mapping impact as use I hospital, and most prestigious viewed
guide guidewire. catheter where specifically unmet our Following new improve can need indications approach to London, our for add several catheter the with uses I I value. guide and and to activities identified opportunity care visited amongst meeting medical had the meet overall other in We of nonelectrophysiologists with and initial France, robotic explore
guide endovascular are by We adoption excited the initiate EP in the adoption in and broader of boost and mapping how field. catheter can robotics
The contributions unique increasingly we broad and to complementary catheters. highlight strategy these expertise APT devices. on from focus efficiently teammates of highly want on additive work Stereotaxis manufacturing APT a new of to and family development is of robotically-stared endovascular I as our of who the the and diligently
attaining milestone the in last us ongoing. catheters, of reviewed regulatory clearance. GenesisX the first a quarter XXX(k) significant FDA sent in for round Beyond October. our development primary several in we was U.S. CE have GenesisX submitting and submission and other and questions for Europe FDA to Mark The efforts
integration on-site of We St. for regulatory have ablation begun approval preparing systems our respond system In to a Louis. in answers catheter. Genesis our working we weeks. and and gain The robot, quality MicroPort, in been coming Chinese to our the audit body completed an Genesis novel have expect partner, regulatory China, the recently mapping NMPA and the with
very near-term reviewers the testament the going audit we'll high-quality the a and primary provide more audit in our There's of much with positive we established. on review a more call keeping well feedback milestones for comprehensive focused on success operations they our to The next on, by but portends China. approvals successful shared that today's The is and team are call.
product key Our is on ecosystem transformational. across X a broad-based progress foundational geographies new
a well line period. to financial results, I'll in call Kim as over a open exciting to I'll financial we particularly are hand and comments Q&A. the to few make before Kim? the We then discuss our
